<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644029</url>
  </required_header>
  <id_info>
    <org_study_id>8591-022</org_study_id>
    <secondary_id>MK-8591-022</secondary_id>
    <secondary_id>2021-001289-39</secondary_id>
    <nct_id>NCT04644029</nct_id>
  </id_info>
  <brief_title>Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)</brief_title>
  <acronym>Impower-022</acronym>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether oral islatravir (ISL) is effective in preventing Human&#xD;
      Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection.&#xD;
      The study will compare oral ISL taken once a month with standard-of-care medication for&#xD;
      prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per&#xD;
      day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the&#xD;
      incidence rate per year of confirmed HIV-1 infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">July 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>A double-blinding technique with in-house blinding will be used. ISL and FTC/TDF and FTC/TAF will be packaged identically relative to their matching placebos so that blind is maintained. The participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the study intervention administration or clinical evaluation of the participants are unaware of the intervention assignments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate Per Year of Confirmed HIV-1 Infections</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections divided by the total person-years of follow-up time to HIV-1 infection status. The primary analysis will compare the incidence rate per year of confirmed HIV-1 Infections between the ISL QM arm participants and incidence rate per year of confirmed HIV-1 Infections in the FTC/TDF QD arm participants. HIV serology tests and polymerase chain reaction (PCR) tests will be done at pre-specified timepoints to confirm HIV-1 infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced One or More Adverse Events</measure>
    <time_frame>Up to approximately 37 months</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign, symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Treatment Due to an Adverse Event</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign, symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate per Year of Confirmed HIV-1 Infections Among Participants</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections divided by the total person-years of follow-up time to HIV-1 infection status. The secondary analysis will compare the incidence rate per year of confirmed HIV-1 Infections between the ISL QM arm participants and the background incidence rate calculated from screened participants. The background incidence rate will be estimated using tests based on biomarkers that can differentiate &quot;recent&quot; from &quot;nonrecent&quot; infections in the population screened for this study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>HIV-I</condition>
  <condition>Human Immunodeficiency Virus Type 1</condition>
  <condition>Prophylaxis</condition>
  <arm_group>
    <arm_group_label>ISL QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISL (islatravir) once monthly AND placebo to FTC/TDF (emtricitabine/tenofovir disoproxil) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTC/TDF QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FTC/TDF (TRUVADA™ or generic product emtricitabine/tenofovir disoproxil) once daily AND placebo to ISL (islatravir) once monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islatravir</intervention_name>
    <description>Oral 60 mg tablet administered once monthly</description>
    <arm_group_label>ISL QM</arm_group_label>
    <other_name>MK-8591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to FTC/TDF</intervention_name>
    <description>0 mg tablet administered once daily</description>
    <arm_group_label>ISL QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF</intervention_name>
    <description>Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily</description>
    <arm_group_label>FTC/TDF QD</arm_group_label>
    <other_name>TRUVADA™</other_name>
    <other_name>Emtricitabine/Tenofovir disoproxil</other_name>
    <other_name>Emtricitabine/Tenofovir disoproxil fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to ISL</intervention_name>
    <description>0 mg tablet administered orally once monthly</description>
    <arm_group_label>FTC/TDF QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results before&#xD;
             randomization.&#xD;
&#xD;
          -  Sexually active (vaginal and/or anal sex) with a male sexual partner in the 30 days&#xD;
             prior to screening.&#xD;
&#xD;
          -  High risk for HIV-1 infection.&#xD;
&#xD;
          -  Not pregnant or breastfeeding, and one of the following conditions applies: Not a&#xD;
             woman of childbearing potential (WOCBP) or is a WOCBP and is using an acceptable&#xD;
             contraceptive method during the intervention period and for at least 42 days after the&#xD;
             last dose.&#xD;
&#xD;
          -  A WOCBP must have a negative pregnancy test within 24 hours prior to the first dose of&#xD;
             study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity or other contraindication to any of the components of the study&#xD;
             interventions as determined by the investigator.&#xD;
&#xD;
          -  Findings of chronic hepatitis B virus (HBV) infection or past HBV.&#xD;
&#xD;
          -  Current or chronic history of liver disease.&#xD;
&#xD;
          -  History of malignancy within 5 years of screening except for adequately-treated basal&#xD;
             cell or squamous cell skin cancer, or in situ cervical cancer.&#xD;
&#xD;
          -  Past or current use of cabotegravir, lenacapavir, or any other long-acting HIV&#xD;
             prevention product.&#xD;
&#xD;
          -  Currently participating in or has participated in an interventional clinical study&#xD;
             with an investigational compound or device, within 30 days prior to Day 1.&#xD;
&#xD;
          -  Expecting to conceive or donate eggs at any time during the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Assigned female sex at birth and is cisgender</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham-UAB Sexual Health Research Clinic (SHRC) ( Site 0064)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-996-4405</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute (MedStar Physician Based R-MedStar Washington Hospital Center ( Si</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-877-0486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Infectious Disease ( Site 0076)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-413-7546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center ( Site 0068)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>40764739602115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ponce De Leon Center Grady Health ( Site 0066)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-251-8940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Mississippi Medical Center ( Site 0065)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>601-815-5009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KC CARE Health Center-Clinical Trials ( Site 0059)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-777-2759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey Medical School-Clinical Research Center ( Site 0071)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>973-803-2463</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bronx Prevention Center ICAP ( Site 0062)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>973-972-3729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill-Medicine ( Site 0056)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-843-9975</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prisma Health Richland Hospital-Clinical Research Unit ( Site 0069)</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>803-960-6775</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prism Health North Texas, Oak Cliff Health Center ( Site 0070)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>972-807-7370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University-Department of Medicine ( Site 0061)</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>302-581-1923</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0023)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27119899711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Reproductive Health and HIV Institute (WRHI)-Wits RHI Ward 21 Clinical Research site ( Site 002</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2000</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27113585414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0020)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+2711 276 8810</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre ( Site 0016)</name>
      <address>
        <city>Tshwane</city>
        <state>Gauteng</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27 12 7992422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SA Medical Research Council - Chatsworth Clinical Research Site ( Site 0030)</name>
      <address>
        <city>Chatsworth</city>
        <state>Kwazulu-Natal</state>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0314014150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternal Adolescent and Child Health Research (MatCH) ( Site 0025)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27310011921</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo Research Clinic ( Site 0017)</name>
      <address>
        <city>Ladysmith</city>
        <state>Kwazulu-Natal</state>
        <zip>3370</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0366312372</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madibeng Centre for Research ( Site 0019)</name>
      <address>
        <city>Brits</city>
        <state>North-West</state>
        <zip>0250</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27232521140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aurum Institute Klerksdorp CRS ( Site 0029)</name>
      <address>
        <city>Klerksdorp</city>
        <state>North-West</state>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27824940748</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aurum Institute - Rustenburg ( Site 0022)</name>
      <address>
        <city>Rustenburg</city>
        <state>North-West</state>
        <zip>2999</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27871351575</phone>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preexposure prophylaxis (PrEP)</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

